302 patents
Page 5 of 16
Utility
Combination Therapy for Treating Cancer
29 Dec 22
The present disclosure provides methods of treating cancer in a patient.
Aatman DOSHI, Alwin SCHULLER, Susan CANTIN
Filed: 2 Nov 20
Utility
Therapeutic Combinations of Acalabrutinib and Capivasertib to Treat B-cell Malignancies
22 Dec 22
The present disclosure relates, in general, to therapeutic combinations of acalabrutinib and capivasertib, and to corresponding methods of treatment, pharmaceutical compositions, and kits.
Hannah DRY, Brandon WILLIS, Andrew BLOECHER, Jerome METTETAL
Filed: 30 Oct 20
Utility
Dry Powder Formulations Containing Leucine and Trileucine
22 Dec 22
The present technology relates generally to dry powder formulations comprising leucine and trileucine in specific ratios that are suitable for pulmonary delivery.
Prakash MANIKWAR, David LECHUGA-BALLESTEROS, Susan HOE, Kellisa Beth HANSEN, Dexter Joseph D'SA, Saba GHAZVINI
Filed: 27 Oct 20
Utility
Pharmaceutical Compositions Comprising AZD9291
15 Dec 22
The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
Cindy FINNIE, Steven Anthony RAW, David WILSON
Filed: 26 Apr 22
Utility
Type I Interferon Inhibition In Systemic Lupus Erythematosus
15 Dec 22
The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE).
Anna BERGLIND, Lilia PINEDA, Raj TUMMALA, Sang-Cheol BAE, Christophe RICHEZ, Anca ASKANASE, Ian BRUCE, Philip BROHAWN, Yoshiya TANAKA, Richard FURIE, Eric MORAND, Gabriel ABREU, Victoria WERTH, Ed VITAL, Michelle KAHLENBERG, David ISENBERG, Ronald Van VOLLENHOVEN, Kenneth KALUNIAN, Rubana KALYANI
Filed: 11 Nov 20
Utility
2-(2,4,5-substituted-anilino)pyrimidine compounds
13 Dec 22
The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant).
Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna Kadambar, Chandrasekhara Reddy Chintakuntla, Andiappan Murugan, Claudio Edmundo Chuaqui
Filed: 12 Nov 20
Utility
Methods of Treating Cancer
8 Dec 22
Methods of treating cancer with a combination of a WEE1 inhibitor and a DNA-damaging agent in patients having SLFN11-deficient cancer cells are disclosed herein.
Elisabetta LEO, Claudia WINKLER, Mark James O'CONNOR, Gemma Nicole JONES, Andrew James PIERCE
Filed: 23 Oct 20
Utility
Halo-substituted Piperidines As Orexin Receptor Modulators
1 Dec 22
The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
Filed: 20 Jul 22
Utility
Lipid Nanoparticles Comprising Lipophilic Anti-inflammatory Agents and Methods of Use Thereof
24 Nov 22
Disclosed herein are lipid nanoparticles comprising a lipid phase and at least one lipophilic anti-inflammatory agent, and pharmaceutical compositions comprising lipid nanoparticles and methods for using lipid nanoparticles.
LENNART LINDFORS, TOMAS KJELLMAN
Filed: 2 Aug 22
Utility
Methods and Combinations for the Treatment of Cancer Using Immune Checkpoint Inhibitor Antibodies
17 Nov 22
The disclosure relates to methods, compositions, and combinations for the treatment of cancer.
John KURLAND, Alejandra NEGRO, Shao-Chun CHANG
Filed: 12 May 21
Utility
Combination Treatment for Cancer
10 Nov 22
The present disclosure provides methods of treating cancer in a patient, comprising administering to the patient a chemotherapeutic agent, an immunomodulatory agent, and an antisense compound targeted to STAT3.
Theresa PROIA
Filed: 29 Sep 20
Utility
Treatment of Lupus Nephritis
3 Nov 22
The disclosure relates to methods and compositions for the treatment of lupus nephritis.
Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE, Teodora TRASIEVA, Wendy WHITE, Dominic SINIBALDI, Madhu RAMASWAMY, Paul NEWCOMBE
Filed: 22 Apr 22
Utility
Chemical Compounds
27 Oct 22
Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases.
Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
Filed: 27 Apr 22
Utility
Dose
27 Oct 22
The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease.
Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE
Filed: 22 Apr 22
Utility
Mcl-1 inhibitors and methods of use thereof
18 Oct 22
Alexander Hird, Matthew Belmonte, Wenzhan Yang, Paul Secrist, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
Filed: 4 Dec 20
Utility
Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
4 Oct 22
The immunostimulatory effect of lipid nanoparticles (LNPs) continues to block their use for safe and effective delivery of pharmaceutical drugs.
Lennart Lindfors, Tomas Kjellman
Filed: 8 May 17
Utility
Compounds
27 Sep 22
Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
Filed: 26 Mar 21
Utility
Halo-substituted piperidines as orexin receptor modulators
6 Sep 22
The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
Filed: 9 Dec 20
Utility
Conjugates for Use In Methods of Treating Cancer
1 Sep 22
Marianne ASHFORD, Srividya BALACHANDER, David OWEN, Christopher John Hamilton PORTER
Filed: 15 Aug 19
Utility
Dendrimer Formulations
1 Sep 22
Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer.
Paul GELLERT, Kathryn HILL, Richard STOREY
Filed: 15 Aug 19